Our Leadership: Imagination Over Iteration
Integrating expertise in biochemistry, chemistry, hardware, molecular biology, photonics, semiconductor chips, and software, our leadership has one thing in common: creating solutions no one has thought of yet and disrupting the status quo to make a global impact on medical research that transforms healthcare.
Leadership
Jeff Hawkins
President and Chief Executive Officer
Mr. Hawkins brings over 20 years of experience at the world’s leading life science and diagnostics companies as an accomplished business leader and inventor. Prior to Quantum-Si, he was President and Chief Executive Officer of Truvian Sciences, Inc. where he led the evolution of the company’s benchtop blood testing system from a product concept through technology feasibility and into late-stage development. Prior to Truvian, Mr. Hawkins led the Reproductive and Genetic Health Business Unit at Illumina, Inc., where he oversaw the rapid global growth of next-generation sequencing into new and emerging markets.
During his Illumina tenure, the business unit more than doubled in revenue and established clear market leadership across every major product line and geographic region. Before Illumina, Mr. Hawkins held roles of increasing responsibility across multiple functional areas for GenMark, Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an MBA from Keller Graduate School of Management. He is co-inventor on 10 issued or pending patents spanning consumables, instrumentation, optics, manufacturing methods and designs.
Todd Bennett
Chief Commercial Officer
Todd brings over 30 years of proven excellence in the biotechnology and in vitro diagnostics sectors. He has served as Chief Commercial Officer or equivalent roles since 2009 at multiple companies. With deep expertise in executive leadership, commercial management, business development, global marketing, strategic planning, and sales, he has driven success across multiple channels, including Life Sciences, Molecular Diagnostics, Point of Care, Clinical Chemistry, Immunoassay, Blood Bank, Hematology, Diabetes Care, and Laboratory Services. His experience spans top industry names such as Abbott Laboratories, Roche Diagnostics, Immucor, Luminex, Binx Health, and Nuclein.
Todd is known for his ability to build and transform commercial organizations, optimize processes, enhance customer service, and develop high-impact strategies that deliver results. His strengths include consultative selling, pipeline development, culture building, and a keen understanding of both small-cap and large, complex organizations.
Todd holds a Bachelor of Science degree in Business Administration with a focus on finance from The Max M. Fisher College of Business at The Ohio State University.
Jeff Keyes
Chief Financial Officer
Mr. Keyes brings over 25 years of experience in senior financial positions providing financial leadership for emerging and evolving public and private companies. Previously, he served as the Chief Financial Officer of Spinal Elements, Inc., a private equity backed medical device company. Prior to Spinal Elements, Mr. Keyes was the Chief Financial Officer of Custopharm, Inc., a private equity backed developer of generic sterile injectable pharmaceuticals, where he helped lead the company through rapid commercial growth and successful acquisition by Hikma Pharmaceuticals. Prior to Custopharm, Mr. Keyes held a variety of leadership roles in life science companies in finance, accounting, and mergers and acquisitions support, and he started his career in public accounting. Mr. Keyes has also served on the board of directors of CNS Pharmaceuticals, Inc., a public clinical stage biotech company, since June 2018. Mr. Keyes earned a B.A. degree in accounting from Western Washington University and is a certified public accountant.
Christian LaPointe, PhD
General Counsel
Christian LaPointe, PhD has served as Quantum-Si’s General Counsel since November 2020. Prior to joining Quantum-Si, Dr. LaPointe served as General Counsel at ArcherDX, Inc., a genomics company, from January 2015 to August 2019, and as Deputy General Counsel at ArcherDX from August 2019 to October 2020. Dr. LaPointe also served as General Counsel to Celsee, Inc., a single cell analysis solutions provider, from August 2019 to June 2020.
Previously, Dr. LaPointe was General Counsel at Thrive Bioscience, Inc., a cell culture instruments and software company, from August 2014 to July 2019, General Counsel of the Enzymatics enzyme solutions unit of QIAGEN N.V., from March 2013 to January 2015, General Counsel of Axios Biosciences, LLC, an oncology drug discovery company, from December 2012 to December 2014, and a litigation attorney at the law firm Sherin and Lodgen LLP from April 2012 to March 2013. Dr. LaPointe received his B.S. in biochemistry from the University of New Hampshire, his PhD in biochemistry from Dartmouth College and his J.D. from Suffolk University Law School.
Todd Rearick
Chief Technology Officer
Todd Rearick has served as Quantum-Si’s Chief Technology Officer since January 2019. Prior to that Mr. Rearick served as Chief Technology Officer at Hyperfine Research from January 2018 to January 2019, and as Systems Engineer from June 2014 to January 2018. Prior to that Mr. Rearick was an Engineering Fellow at Life Technologies from October 2010 to June 2014, and Principal Engineer for Ion Torrent from May 2008 to October 2010.
Prior to that Mr. Rearick was a Software Manager at Raindance Technologies from June 2006 to May 2008, and held several positions at Sycamore Networks, a telecommunications equipment manufacturer, from April 1999 to June 2006. Mr. Rearick started his career with the Naval Undersea Warfare Center (NUWC) in New London, Connecticut from 1995 to 1998. Mr. Rearick earned his B.S. in Engineering Science from Penn State University.
Lindsay Thompson
Chief Human Resources Officer
Lindsay Thompson serves as the Chief Human Resources Officer of Quantum-Si, where she leads all aspects of people operations, recruitment, culture and compensation/benefits. She has been with the company full time since June 2021 but was previously supporting the company while under the 4Catalyzer incubator since June 2019.
Prior to that, Ms. Thompson served in various HR capacities in banking, financial services, distribution, manufacturing and insurance. Ms. Thompson received her B.S. in Business Administration and currently holds her SHRM (Society for Human Resources Management) certification.
John Vieceli, PhD
Chief Product Officer
John Vieceli, PhD serves as the Chief Product Officer of Quantum-Si, where he leads Product Development and Operations. He is an accomplished senior leader with nearly two decades of experience building and mentoring technical teams, bringing early-stage technology development to market, and leading strategic programs. Dr. Vieceli joined Quantum Si in December 2022 and has held positions of increasing responsibility in Software and Informatics and Product Development.
Prior to that, he held leadership positions at various next generation DNA sequencing companies, including Illumina, Omniome, and Pacific Biosciences. His work has focused on areas such as bioinformatics, image and signal processing, and computer subsystems for sequencing instruments. Dr. Vieceli was awarded the Illumina Annual Innovation Award in 2022 for signal processing improvements that resulted in significantly higher sequencing accuracy. Prior to that, his technical work on patterned flow cells and new sequencing chemistries played a key role in driving down the cost of human genome sequencing below $1,000 at Illumina. He is an inventor on over 25 patent filings in the areas of nanofabrication, signal processing algorithms, and assay development and an author on over 20 publications in DNA sequencing and surface chemistry. Dr. Vieceli received his PhD in Theoretical Physical Chemistry from the University of California, Santa Cruz and his B.S. in Biology and Chemistry from Santa Clara University.